Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have found that a daily oxaloacetate supplement may help relieve persistent brain fog and fatigue in breast cancer survivors.
Oxaloacetate Improves Cognitive Scores in Breast Cancer Survivors
- The Molecule: Oxaloacetate is a naturally occurring cellular energy compound found inside the human body.
- The Trial: A phase II clinical trial tracked 18 early-stage breast cancer survivors taking 500 milligrams of the supplement twice daily for eight weeks.
- The Results: Participants reported significant improvements in memory, processing speed, and mental exhaustion, pushing average cognitive scores from impaired into normal ranges.
UCLA Trial Tracks Oxaloacetate Supplementation
Breast cancer survivors frequently experience long-term cognitive difficulties, often described as chemo brain or brain fog, which can persist for years after treatment concludes. Researchers estimate that roughly 15% to 25% of survivors face ongoing problems with memory and concentration.
These persistent symptoms can interfere with daily life, yet effective clinical treatments remain sparse. To address this gap, investigators at UCLA evaluated whether a supplement containing oxaloacetate could improve mental clarity and physical energy in affected patients.
The phase II clinical trial enrolled 18 women diagnosed with early-stage breast cancer between one and five years prior. Participants had an average age of 50 and reported substantial cognitive difficulties entering the study. Most had undergone chemotherapy, and nearly 90% maintained ongoing endocrine therapy regimens throughout the intervention period. Each patient ingested 500 milligrams of oxaloacetate twice daily across eight consecutive weeks.
Investigators tracked symptom changes using standardized participant questionnaires alongside formal tests evaluating memory, attention, processing speed, and executive function. Executive function governs the mental skills required to organize tasks, maintain focus, and manage daily plans. The research team also monitored broader measures including sleep, anxiety, depression, and physical well-being. Side effects were tracked continuously during the supplementation window.
Participants Reported Relief from Cognitive Symptoms During the Trial
Sixteen of the 18 enrolled women completed the full eight-week trial protocol. Every participant who finished the course reported measurable relief from their cognitive symptoms. Prior to supplementation, the group recorded an average perceived cognitive impairment score of 29.1. By week eight, that average climbed to 55.5, shifting the cohort into a normal functioning classification.
Initial signs of improvement emerged at the four-week mark and continued to compound over time. Objective cognitive testing supported these self-reported gains, highlighting faster information processing speeds and sharper executive function. Participants simultaneously noted reductions in mental exhaustion and physical fatigue.
| Study Metric | Baseline (Week 0) | Post-Intervention (Week 8) |
|---|---|---|
| Perceived Cognitive Impairment Score | 29.1 (Impaired Range) | 55.5 (Normal Range) |
| Participant Completion Rate | 18 Enrolled | 16 Completed |
| Supplement Dosage | 500 mg (Twice Daily) | 500 mg (Twice Daily) |
Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it,
said Dr. Patricia Ganz, the study’s first author and a distinguished professor of medicine at UCLA’s David Geffen School of Medicine and UCLA Fielding School of Public Health.
Broader Physiological Mechanisms and Funding
Oxaloacetate captured researcher attention because it participates directly in cellular energy production and regulates glutamate signaling. By providing additional oxaloacetate, scientists aimed to counteract these biological disruptions. The study received partial financial backing from the Breast Cancer Research Foundation and the National Cancer Institute.
These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment,
Ganz said. The research team is currently preparing a larger, randomized, placebo-controlled phase II trial to confirm these preliminary outcomes. Parallel preclinical trials in animal models are also underway to map the exact neurological mechanisms at play.
Gastrointestinal Side Effects Require Medical Consultation
Reported side effects included indigestion, bloating, constipation, diarrhea, and nausea. Two participants discontinued supplementation due to gastrointestinal discomfort. No serious adverse events were recorded during the investigation. Patients experiencing persistent cognitive decline or fatigue following cancer treatment must consult an oncologist or primary care physician before initiating new supplements, as these symptoms can stem from diverse medical causes requiring professional evaluation.
References
- JCO Oncology Advances — Early clinical findings on oxaloacetate for cancer-related cognitive impairment.
- UCLA Health Jonsson Comprehensive Cancer Center — Clinical trial data and participant metrics.
- Breast Cancer Research Foundation — Research funding and grant documentation.
- National Cancer Institute — Federal research support records.
